REDWOOD CITY, Calif.--(BUSINESS WIRE)--Maxygen, Inc. (Nasdaq:MAXY), a biotechnology company focused on the development of improved protein drugs, today announced that it has sold its MolecularBreeding™ platform technology to Codexis, Inc. (Nasdaq:CDXS) for $20 million in cash. The sale included the cancellation of all payment and potential royalty obligations of Codexis to the company relating to biofuels and other energy products.
